The turning point was the integration process between Ulisse Biomed and Hyris: an operation that began in 2023 and was completed in 2024, combining industrial expertise and technological development in a single trajectory. The rebranding to Helyx Industries S.p.A. is not a cosmetic change: it is the formalisation of industrial maturity and a clearer structure towards the market.
Today, Helyx means overseeing the entire stack, instruments, software, reagents and services, with three complementary divisions that make the offering more readable and scalable. And it means doing so with the governance and transparency standards of a listed company.

Two priorities: industrial discipline and consistency of execution. On the one hand, aligning processes, quality and governance to enable the Group to operate as a single system, with clear rules and defined responsibilities. On the other, transforming integration into operational choices: realistic roadmaps, a focus on scalability, and rigorous management of what we develop internally versus what we enable through partners. For us, value is measured by our ability to deliver reliable, replicable and sustainable solutions over time.

The logic is simple: three areas, three industrial "engines". Hyris covers distributed qPCR and operations in decentralised contexts; Vytro focuses on PCR solutions in laboratories and IVDs, with advanced approaches such as deep multiplexing; Mytho develops tailor-made NGS, with custom panels and advanced bioinformatics. This clarity reduces commercial and technical ambiguity: each stakeholder immediately knows where their use case fits in and how it integrates with the rest of the Group.

We are working on a multi-year roadmap with a specific goal: to make molecular diagnostics more accessible, more scalable and more integrable into real-world clinical and industrial processes. This means pushing for product innovation and expanding the diagnostic menu, but also focusing on less visible yet decisive aspects: workflow automation, reliability, interoperability and industrialisation capabilities.
At the same time, we want to strengthen our international presence and partnerships, maintaining a pragmatic approach: growing where technology solves concrete problems and where we can guarantee quality and consistent execution over time.

We believe in it because it changes the relationship between data and decision-making. Decentralised diagnostics is not about 'testing outside the laboratory' as a matter of principle: it is about bringing analytical capabilities where they are needed, when they are needed, reducing logistical friction and downtime. With the Hyris division, the approach revolves around Hyris System™: an ecosystem that combines compact qPCR instruments (bCUBE™) and a cloud platform (bAPP™) for controlling, managing and interpreting results. This enables concrete scenarios: from use in hospital wards to field contexts, where data must be available quickly and shareable in a structured way. For us, the difference lies in the combination of operability, connectivity and platform model, not in the individual device.

For us, sustainability means two things above all else: access and operational responsibility. Access, because bringing tools and tests to resource-limited settings has a direct social impact; operational responsibility, because every technological choice has logistical and energy consequences.
One example is the development of reagents designed to reduce storage and logistical constraints, and more generally, the evolution of solutions that make diagnostics feasible even in complex scenarios. 
Finally, there is supply chain sustainability: development and OEM services enable technology to be transferred in an orderly and scalable manner, including through structured industrial partnerships.

Our positioning is that of an integrated industrial group with an international presence and a model that combines direct solutions and collaboration with partners. Diversification, if poorly managed, creates noise; if well managed, it creates resilience. The key is to maintain a coherent core: reusable platforms and skills, adapted to different contexts. Modularity helps us stay focused: we do not chase markets, but use cases where our technologies are truly enabling.

This is something we care deeply about: innovation and accessibility must go hand in hand. Technology only has a real impact if it is used, and used well. That's why we design with the end user in mind, who is not always a PhD in a laboratory. In concrete terms: simplification and usability. The system is designed to reduce operational complexity, with plug & play logic and management via web app (bAPP™), which can also be used on the move. In addition, the integration of proprietary AI modules into the software supports data analysis and interpretation, reducing manual tasks and the risk of error. The picture is completed by structured support and, where appropriate, services that facilitate adoption without weighing down operations.

It is a huge responsibility, but also an extraordinary source of motivation. I approach this role with humility and determination: I know that I have the task of guiding the strategic vision, but I also know that nothing can be achieved without a great team. In a rapidly expanding biotech company, two needs must be balanced: maintaining the drive for innovation while building a solid and sustainable organisational structure. As a leader, I feel I must be the guardian of the long-term vision and the guarantor of short-term reliability: delivering concrete results with seriousness and transparency.

For us, "innovation" is not just a claim, but a measurable commitment. We want to build solutions that work in everyday life, in the laboratory, in the hospital, in the field, with reliability and rigour. And we want to do so with an open approach to partnerships: when it makes sense industrially, we collaborate; when we need to protect quality and consistency, we integrate.
Helyx aims to bring molecular biology towards more accessible, connected and industrialisable models, without shortcuts.